Molecular Therapy-nucleic Acids

SCI SCIE

国际简称：MOL THER-NUCL ACIDS 参考译名：分子疗法-核酸

主要研究方向：MEDICINE, RESEARCH & EXPERIMENTAL 非预警期刊审稿周期：20 Weeks

《分子疗法-核酸》(Molecular Therapy-nucleic Acids)是一本由Cell Press出版的以MEDICINE, RESEARCH & EXPERIMENTAL为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

2区中科院分区
Q1 JCR分区
280 年发文量
6.5 IF影响因子
开放是否OA
43 H-index
2012 创刊年份
4 issues/year 出版周期
English 出版语言

Molecular Therapy — Nucleic Acids publishes research targeted to the advances in nucleic acid-based therapeutics to treat and/or correct genetic and acquired disease. Subject areas include: development of therapeutics based on nucleic acids and their derivatives, vector development and design for the delivery of RNA-based therapeutics, and applications of gene-modifying agents.

[ 查看全部 ]

投稿咨询加急咨询

Molecular Therapy-nucleic Acids期刊信息

ISSN：2162-2531
出版语言：English
是否OA：开放
E-ISSN：2162-2531
出版地区：UNITED STATES
是否预警：否
出版商：Cell Press
出版周期：4 issues/year
创刊时间：2012
开源占比：0.9171
Gold OA文章占比：100.00%
OA被引用占比：1
出版国人文章占比：0.48
出版撤稿占比：0
研究类文章占比：84.64%

Molecular Therapy-nucleic Acids CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

10.8

2.068

1.096

学科类别	分区	排名	百分位
大类：Pharmacology, Toxicology and Pharmaceutics 小类：Drug Discovery	Q1	23 / 161	86%
大类：Pharmacology, Toxicology and Pharmaceutics 小类：Molecular Medicine	Q1	27 / 179	85%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Molecular Therapy-nucleic Acids中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
是	否	医学	2区	MEDICINE, RESEARCH & EXPERIMENTAL 医学：研究与实验	2区

Molecular Therapy-nucleic Acids JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	37 / 191	80.9
学科：MEDICINE, RESEARCH & EXPERIMENTAL	SCIE	Q1	26 / 191	86.65

Molecular Therapy-nucleic Acids历年数据统计

影响因子

中科院分区

Molecular Therapy-nucleic Acids中国学者发文选摘

1、Safety, efficacy, and distal nerve Schwann cell biodistribution in mice and NHPs to support translation of AAV9 RNAi therapy for CMT1
Author: Stavrou, Marina; Wallace, Lindsay M.; Thangaraj, Merlin P.; Taylor, Noah K.; Kagiava, Alexia; Papacharalambous, Revekka; Mcallister, Cynthia; Zender, Gloria; Saad, Nizar Y.; Bayazit, M. Bilal; Heslegrave, Amanda; Tryfonos, Christina; Richter, Jan; Zetterberg, Henrik; Price, Brian; Salzman, Rachel; Kleopa, Kleopas A.; Harper, Scott Q

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 2, pp. -. DOI: 10.1016/j.omtn.2026.102881
2、Multi-layer molecular profiling defines an immune-active colorectal cancer subtype with therapeutic relevanc
Author: Zou, Miao; Wang, Zuxiang; Zhou, Wenyang; Xue, Guangfu; Hui, Yi; Pang, Fenglan; Tan, Renjie; Xu, Zhaochun; Jin, Xiyun; Sun, Haoxiu; Wang, Pingping; Jiang, Qinghua

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 2, pp. -. DOI: 10.1016/j.omtn.2026.102907
3、Unlocking the potential of mRNA nanomedicines for comprehensive fibrosis therap
Author: Yang, Yue; Li, Chaofu; Xiong, Weidong; Li, Chuanwei; Xiao, Jun

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 2, pp. -. DOI: 10.1016/j.omtn.2026.102917
4、c-Jun in neurodegeneration: A key transcriptional regulator with therapeutic implication
Author: Khan, Faiz Ali; Khan, Hizbullah; Awan, Usman Ayub; Nurahmat, Mammat; Nabijan, Mohammadtursun; Abduwaki, Muhammadjan; Dong, Jingcheng

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 2, pp. -. DOI: 10.1016/j.omtn.2026.102874
5、TiSMeD: A tissue-specific methylation and expression database for biomarker and translational application
Author: Cheng, Jiao; Lin, Zhe; Wu, Lvying; Li, Qianying; Yin, Huajun; Wang, Hao; Chen, Hao; Chen, Xiaoyan; Ji, Zhi-Liang

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 2, pp. -. DOI: 10.1016/j.omtn.2026.102884
6、TIPE2 gene knockdown in mice attenuates experimental colitis by diminishing inflammatory cell infiltratio
Author: Tang, Yexiao; Li, Ping; Li, Minghui; Zhang, Pengchao; Lu, Zhen; Qiao, Hang; Wei, Jing; Xu, Zhiming; Wan, Xiaochun; Xu, Shu; Chen, Youhai H.; Zhang, Guizhong

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 2, pp. -. DOI: 10.1016/j.omtn.2026.102887
7、Potential effects of endogenous RNA/DNA hybrids on CRISPR-Cas9-mediated homology-directed repai
Author: Puzzo, Francesco; Bayram, Batuhan; Macaubas, Claudia; Lin, Angela; Jang, Hagoon; Zhang, Feijie; Mellins, Elizabeth; Kay, Mark A

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 2, pp. -. DOI: 10.1016/j.omtn.2026.102880
8、Rabies lyssavirus phosphoprotein possesses RNA duplex-unwinding activitie
Author: Mu, Jingfang; Wang, Caiqian; Shu, Ting; Xiong, Xiaobei; Ren, Yujie; Gong, Rui; Zhao, Ling; Zhou, Xi

Journal: MOLECULAR THERAPY NUCLEIC ACIDS. 2026; Vol. 37, Issue 1, pp. -. DOI: 10.1016/j.omtn.2026.102863